TECHNICAL
DATA
SHEET

Fluorescent Imaging Agent
Caution: For Laboratory Use. A product for research purposes only.

IntegriSense™ 645
Product Number: NEV10640

DESCRIPTION: IntegriSense™ 645 is a targeted fluorescent imaging agent comprising a potent, selective non-peptide
small molecule integrin αvβ3 antagonist and a near-infrared (NIR) fluorochrome. This agent has been developed to enable invivo visualization and quantification of integrin expressed in tumor cells as well as in neovasculature, to monitor tumor
growth, tumor angiogenesis, and treatment efficacy. Half-life of IntegriSense 645 in tissue is approximately 2 days.

MATERIAL:CONTENTS: Each vial contains 24 nmol of IntegriSense
645 as a 20 µM solution in 1 x PBS which has been filteredthrough a 0.2 µm filter prior to filling. The solution is ready forinjection. The packaged material provides sufficient reagent
for imaging approximately 10 mice (weighing ~25 grams each)when using the recommended dose of 2 nmol (100 µL) ofIntegriSense 645 per mouse.
PROPERTIES: The physical characteristics ofTable 1. IntegriSense 645 Characteristics
Property
SpecificationMW~ 1250 g mol-1
Fluorescence1
 Excitation
649 nm Emission
666 nmAbsorbance1
649 nmPurity2>90%
Appearance
Clear blue solution

1. Absorbance and fluorescence maxima of IntegriSense 645 in
1x PBS.
2. As determined by RP-HPLC and measuring absorbance at645 nm.

IntegriSense 645 can be found in Table 1 and Figure 1.

STORAGE & HANDLING:


Upon receipt, IntegriSense 645 should be
IMMEDIATELY STORED AT
2-8 oC AND PROTECTED FROM LIGHT.
When stored and handled properly, IntegriSense 645 is
stable for up to three months as a PBS solution at 2-8ºC and protected from light from the date of shipment.

10.8
0.6
0.4
0.20450500550600650700750800wavelength (nm)IN VIVO IMAGING AND APPLICATIONS:The generally recommended procedure for in vivo
Figure 1. Normalized absorbance (blue) andimaging with IntegriSense 645 is administration via
fluorescence emission (red) spectra of IntegriSense 645
intravenous injection and imaging 6-24 hours postin 1x PBS.
injection.
Imaging may be performed as early as 3 hours withsome reduction in target signal/noise.
IntegriSense 645 will clear from tissues after approximately 6-7 days. Repeat injection and imaging may be
performed every 3 days for longitudinal studies. It is recommended that a pre-injection baseline image be taken prior
to reinjection and imaging, unless injections are performed every 7 days.
IntegriSense 645 enables imaging of tumors and neovasculature in a range of oncology applications.

Page 1 of 2

NOTES:
PerkinElmer’s IntegriSense 645 is intended for research purposes only and is not for human use. It must be used byor directly under the supervision of a technically qualified individual experienced in handling potentially hazardous
materials. Please read the Material Safety Data Sheet (MSDS) provided for this product.

Several of PerkinElmer’s products and product applications are covered by U.S. and foreign patents and patents
pending. Our products are not available for resale or other commercial uses without a specific agreement withPerkinElmer.

PerkinElmer, Inc.
549 Albany Street
Boston, MA 02118 USA
P: (800) 762-4000 or (+1) 203-925-4602
www.perkinelmer.com/nenradiochemicals
For a complete listing of our global offices, visit www.perkinelmer.com/ContactUs
Copyright ©2010, PerkinElmer, Inc. All rights reserved. PerkinElmer® is a registered trademark of PerkinElmer, Inc.
All other trademarks are the property of their respective owners.